Abstract
Adjuvant radiation therapy (RT) for resectable pancreatic cancer remains controversial. Sub-populations of radiosensitive pancreatic tumors might exist given genetic heterogeneity. We compared pancreatic cancer radiosensitivity with other common cancers using a previously validated molecular signature of tumor radiosensitivity (RSI) and evaluated whether RSI could predict survival outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
